Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disruptive Pharma ABOSTO:DPHA +0.83%4 EV-to-FCF is -0.76 as of Sep. 22, 2026. GuruFocus rates OSTO:DPHA with a GF Score™ of 4/100. Among 573 Drug Manufacturers companies, Disruptive Pharma AB ranks worse than 174519.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Disruptive Pharma AB's Enterprise Value is kr49.87 Mil.
Disruptive Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was kr-65.28 Mil. Therefore, Disruptive Pharma AB's EV-to-FCF for today is -0.76.
The historical rank and industry rank for Disruptive Pharma AB's EV-to-FCF or its related term are showing as below:
OSTO:DPHA'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.64 Med: 0 Max: 0
Current: -2.64
OSTO:DPHA's EV-to-FCF is ranked worse than 100% of 573
companies
in the Drug Manufacturers industry
Industry Median: 19.25
vs OSTO:DPHA: -2.64
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Disruptive Pharma AB (OSTO:DPHA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Disruptive Pharma AB's PE Ratio (TTM) for today is calculated as:
Disruptive Pharma AB's share price for today is kr1.21.
Disruptive Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.634.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Disruptive Pharma AB EV-to-FCF Related Terms
Disruptive Pharma AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Disruptive Pharma AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disruptive Pharma AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Disruptive Pharma AB's EV-to-FCF falls into.
Disruptive Pharma AB's current Enterprise Value is kr49.87 Mil.
Disruptive Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-65.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disruptive Pharma AB (OSTO:DPHA) has a EV-to-FCF of -0.76 as of Sep. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Disruptive Pharma AB and its competitors. According to the industry distribution chart, Disruptive Pharma AB ranks #999999 out of 573 companies in the Drug Manufacturers industry.
Is Disruptive Pharma AB's EV-to-FCF too high?
Disruptive Pharma AB's current EV-to-FCF is -0.76. Based on the distribution chart, Disruptive Pharma AB ranks #999999 out of 573 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's EV-to-FCF compare to ?
According to the Drug Manufacturers industry distribution chart, Disruptive Pharma AB ranks #999999 out of 573 companies for EV-to-FCF. This places Disruptive Pharma AB in the lower half of its industry. The industry median EV-to-FCF is 19.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.25, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Disruptive Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disruptive Pharma AB's current EV-to-FCF is -0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (OSTO:DPHA) has a current EV-to-FCF of -0.76. The current EV-to-FCF is -0.76. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Disruptive Pharma AB (OSTO:DPHA), the current EV-to-FCF is -0.76 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score
Get the complete analysis for OSTO:DPHA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DPHA has been successfully added to your 
